Some of the most popular graduate degrees don’t pay off financially, study finds

A new study finds some popular graduate degrees deliver little or negative financial return: advanced degrees in social work and psychology may show zero to negative returns. By contrast, medicine, law and pharmacy degrees rank among the highest-return advanced degrees. The finding is relevant for prospective students and lenders weighing program cost versus expected earnings, but it is unlikely to move financial markets materially.

Analysis

Universities will respond to heterogeneous private returns by reallocating scarce enrollment and faculty resources toward programs with clearer employer demand and margin capture; expect a 2–5 year shift in program mix that disproportionately benefits online program managers and campus-light providers that can scale professional masters and credential bundles at lower marginal cost. That reallocation will compress admissions and tuition subsidies for low-ROI fields, producing a structural decline in graduate enrollment in those disciplines of perhaps 10–30% regionally over several recruitment cycles.

On the funding side, private lenders, servicers, and ABS buyers will reprice risk across cohorts as cohort-level earnings diverge: cohorts from workforce-aligned programs should see lower default and higher prepayment rates within 3–6 years, while cohorts from low-return programs could increase loss severity and extend duration. This creates a convexity opportunity for credit investors to overweight claim structures tied to high-earning grads and to hedge policy shock risk (e.g., broad forgiveness or tuition caps) that would reflate demand for low-ROI programs.

Employers will accelerate skills-based hiring and substitute firm-funded training for credential inflation where possible, pressuring wages at the lower end of the professional ladder but increasing spend on clinical and legal talent that remains scarce; staffing and specialty recruiting firms are likely to capture most of the employer-side spending uplift. Lastly, demographic headwinds (fewer 18–24 year-olds) and potential regulatory interventions form the obvious reversal catalysts — both operate on multi-year horizons but can crystallize quickly if policy shifts, meaning positions should be sized with event risk in mind.

Key Decisions for Investors

• Long TWOU (2U) — buy a 12-month call spread (e.g., buy 2U Jan-2027 $12 calls / sell $20 calls) to express reallocation toward scalable, workforce-aligned graduate programs. Entry: now. Target: 30–60% upside if universities accelerate outsource/partner deals within 12 months. Risk: 30%+ premium loss if enrollment growth disappoints or competition compresses pricing.
• Long AMN (AMN Healthcare) — buy shares or 9–12 month ATM calls to capture outsized pricing power for specialty clinical staffing as employer-funded staffing budgets rise. Entry: staged over 3 months. Target: 20–35% total return as utilization and contract rates normalize higher; downside: 20–30% if hospital payroll absorption or regulatory pressure reduces outsourcing.
• Pair trade: Long LOPE (Grand Canyon Education) / Short CHGG (Chegg) — long a controlled-campus, program-centric educator vs short consumer-facing, cyclical study-aid exposure. Timeframe: 6–12 months. Target pair spread: 20–30% relative outperformance. Risks: LOPE enrollment softness or CHGG execution upside could invert outcome; size as a directional pair to limit market beta.